BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22865337)

  • 1. Molecular diagnostic tools for the detection of nodal micrometastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: a prospective study.
    Vagnoni V; Schiavina R; Romagnoli D; Borghesi M; Passaretti G; Dababneh H; Concetti S; Martorana G
    Urologia; 2012 Dec; 79 Suppl 19():141-6. PubMed ID: 22865337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
    Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
    Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy.
    Terakawa T; Miyake H; Kurahashi T; Furukawa J; Takenaka A; Fujisawa M
    BJU Int; 2009 Apr; 103(8):1074-8. PubMed ID: 19348036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
    Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
    Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
    Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
    BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic lymph node dissection in prostate cancer.
    Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
    Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
    Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
    Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodal occult metastases in intermediate- and high-risk prostate cancer patients detected using serial section, immunohistochemistry, and real-time reverse transcriptase polymerase chain reaction: prospective evaluation with matched-pair analysis.
    Schiavina R; Capizzi E; Borghesi M; Vagnoni V; Romagnoli D; Rocca GC; Giunchi F; D'Errico A; De Giovanni A; Rizzi S; Brunocilla E; Martorana G; Fiorentino M
    Clin Genitourin Cancer; 2015 Apr; 13(2):e55-64. PubMed ID: 25212578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.
    Hijazi S; Meller B; Leitsmann C; Strauss A; Meller J; Ritter CO; Lotz J; Schildhaus HU; Trojan L; Sahlmann CO
    Prostate; 2015 Dec; 75(16):1934-40. PubMed ID: 26356236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.
    Miyake H; Hara I; Kurahashi T; Inoue TA; Eto H; Fujisawa M
    Clin Cancer Res; 2007 Feb; 13(4):1192-7. PubMed ID: 17317829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.
    Heidenreich A; Ohlmann CH; Polyakov S
    Eur Urol; 2007 Jul; 52(1):29-37. PubMed ID: 17448592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population.
    Sengupta S; Weerakoon M; Sethi K; Ischia J; Webb DR
    BJU Int; 2012 Apr; 109 Suppl 3():48-51. PubMed ID: 22458494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
    Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
    Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
    Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
    Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.
    Kluth LA; Abdollah F; Xylinas E; Rieken M; Fajkovic H; Sun M; Karakiewicz PI; Seitz C; Schramek P; Herman MP; Becker A; Loidl W; Pummer K; Nonis A; Lee RK; Lotan Y; Scherr DS; Seiler D; Chun FK; Graefen M; Tewari A; Gönen M; Montorsi F; Shariat SF; Briganti A
    Eur Urol; 2014 Sep; 66(3):439-46. PubMed ID: 23850255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy.
    Liu DY; Xia WM; Tang Q; Wang J; Wang MW; Wang Y; Wang SJ; Ye YF; Zhou WL; Shao Y
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):235-41. PubMed ID: 24292502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer.
    Porcaro AB; de Luyk N; Corsi P; Sebben M; Tafuri A; Tamanini I; Processali T; Cerruto MA; Migliorini F; Brunelli M; Siracusano S; Artibani W
    Tumori; 2017 May; 103(3):299-306. PubMed ID: 27716882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.